6V97
 
 | Kindlin-3 double deletion mutant short form | Descriptor: | Fermitin family homolog 3 | Authors: | Xu, Z, Zhang, T.L, Xu, Z, Sun, J.J, Ding, J.P, Ma, Y.Q. | Deposit date: | 2019-12-13 | Release date: | 2020-07-22 | Last modified: | 2023-10-11 | Method: | X-RAY DIFFRACTION (2.381 Å) | Cite: | Structure basis of the FERM domain of kindlin-3 in supporting integrin alpha IIb beta 3 activation in platelets. Blood Adv, 4, 2020
|
|
6V9G
 
 | Kindlin-3 double deletion mutant long form | Descriptor: | Fermitin family homolog 3 | Authors: | Xu, Z, Zhang, T.L, Xu, Z, Sun, J.J, Ding, J.P, Ma, Y.Q. | Deposit date: | 2019-12-13 | Release date: | 2020-07-22 | Last modified: | 2023-10-11 | Method: | X-RAY DIFFRACTION (2.35 Å) | Cite: | Structure basis of the FERM domain of kindlin-3 in supporting integrin alpha IIb beta 3 activation in platelets. Blood Adv, 4, 2020
|
|
3P5B
 
 | The structure of the LDLR/PCSK9 complex reveals the receptor in an extended conformation | Descriptor: | CALCIUM ION, Low density lipoprotein receptor variant, Proprotein convertase subtilisin/kexin type 9 | Authors: | Lo Surdo, P, Bottomley, M.J, Calzetta, A, Settembre, E.C, Cirillo, A, Pandit, S, Ni, Y, Hubbard, B, Sitlani, A, Carfi, A. | Deposit date: | 2010-10-08 | Release date: | 2011-10-26 | Last modified: | 2024-11-20 | Method: | X-RAY DIFFRACTION (3.3 Å) | Cite: | Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH. Embo Rep., 12, 2011
|
|
3P5C
 
 | The structure of the LDLR/PCSK9 complex reveals the receptor in an extended conformation | Descriptor: | CALCIUM ION, Low density lipoprotein receptor variant, Proprotein convertase subtilisin/kexin type 9 | Authors: | Lo Surdo, P, Bottomley, M.J, Calzetta, A, Settembre, E.C, Cirillo, A, Pandit, S, Ni, Y, Hubbard, B, Sitlani, A, Carfi, A. | Deposit date: | 2010-10-08 | Release date: | 2011-10-26 | Last modified: | 2024-11-06 | Method: | X-RAY DIFFRACTION (4.2 Å) | Cite: | Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH. Embo Rep., 12, 2011
|
|
7V97
 
 | Arsenic-bound p53 DNA-binding domain mutant V272M | Descriptor: | ARSENIC, Cellular tumor antigen p53, ZINC ION | Authors: | Lu, M, Xing, Y.F, Wang, Z.Y, Ni, Y, Song, H.X. | Deposit date: | 2021-08-24 | Release date: | 2022-08-31 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (2.02 Å) | Cite: | Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties. Sci Transl Med, 15, 2023
|
|
4FCB
 
 | Potent and Selective Phosphodiesterase 10A Inhibitors | Descriptor: | 3,4-dimethyl-1-propyl-7-(quinolin-2-ylmethoxy)imidazo[1,5-a]quinoxaline, MAGNESIUM ION, ZINC ION, ... | Authors: | Parris, K.D. | Deposit date: | 2012-05-24 | Release date: | 2012-09-05 | Last modified: | 2024-02-28 | Method: | X-RAY DIFFRACTION (2.1 Å) | Cite: | Novel triazines as potent and selective phosphodiesterase 10A inhibitors. Bioorg.Med.Chem.Lett., 22, 2012
|
|
4FCD
 
 | Potent and Selective Phosphodiesterase 10A Inhibitors | Descriptor: | 1-(2-chlorophenyl)-6,8-dimethoxy-3-methylimidazo[5,1-c][1,2,4]benzotriazine, MAGNESIUM ION, ZINC ION, ... | Authors: | Parris, K.D. | Deposit date: | 2012-05-24 | Release date: | 2012-09-05 | Last modified: | 2024-02-28 | Method: | X-RAY DIFFRACTION (2.02 Å) | Cite: | Novel triazines as potent and selective phosphodiesterase 10A inhibitors. Bioorg.Med.Chem.Lett., 22, 2012
|
|